Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Healthcare

Deciphex decodes $2.6m
Based at DCU Invent, Deciphex has gained investors including Inova and GI Partners as it looks to refine its offering for the toxicologic and gastrointestinal segments of pathology.
Michigan marks Applied Morphomics
Applied Morphomics has formally spun out of University of Michigan to deliver a medical analytics service powered by morphological scans of patients.
Oxford Brain Diagnostics secures funding
Oxford Brain Diagnostics hopes to commercialise an early diagnosis tool for Alzheimer’s disease pioneered through eight years of University of Oxford research.
Think-Lands needles $3m
Building on Chiba and Hokkaido university research, Think-Lands is aiming to commercialise microneedles manufactured with its optical vortex production system.
Talaris takes home $100m series A
Talaris, previously known as Regenerex and based on research at University of Louisville, will use the funding to advance its cell therapy into later-stage clinical development.
Arrakis arranges $75m series B
Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.
Morley continues to make his mark on Pitt
Scott Morley has been appointed as director of the [email protected] medtech accelerator, in addition to his duties as entrepreneur-in-residence at the university's Innovation Institute.
Gyroscope enters Orbit for merger
Gyroscope Therapeutics, spun out of Cambridge and Syncona, has merged with Orbit Biomedical to form a fully-integrated retinal gene therapy developer.

Other News

Happe Spine erects funding round
Based on research at University of Notre Dame, Happe Spine is working on implants for interbody spinal fusion.
Imprimed sniffs out $4m investment
Stanford-StartX Fund has supported a $4m round for Imprimed, which is working on precision cancer treatments for dogs.
Willow Biosciences follows public path
Willow Biosciences is the result of a three-way merger between University of Calgary spinout Epimeron, BioCan Technologies and CSE-listed Makena Resources.
Cardinal Analytx processes series B
Stanford spinout Cardinal Analytx has raised $20.6m out of a targeted $29.3m, adding to a $6.1m series A round backed by Stanford-StartX Fund in 2017.
AskBio pops $235m question
Asklepios BioPharmaceutical, based on work by UNC Chapel Hill professors Jude Samulski and Xiao Xiao, has secured $235m in funding co-led by TPG Capital and Vida Ventures.
Nanology Labs finds Facit for funding
The Toronto oncological MRI agent spinout has been backed by Facit’s Prospects Oncology vehicle, to target applications including the identification and treatment of tumours in the brain.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
test reg

Login